Shares of Interarch Building Solutions Limited (BSE: 544232 | NSE: INTERARCH) rose nearly 3% on Wednesday, September 17, after the company announced two key milestones in its manufacturing expansion journey. The stock gained 2.90% to Rs 2,132.90, up Rs 60.10, giving the company a market capitalization of Rs 3,583 crore on the NSE.
The company said it has commissioned Phase 2 of its Pre-Engineered Buildings (PEB) plant in Andhra Pradesh and inaugurated a state-of-the-art Box Column Line at its Kichha facility in Uttarakhand. Together, these projects represent a total investment of Rs 53 crore and are expected to generate over 200 direct and indirect employment opportunities.
In Andhra Pradesh, the Phase 2 expansion at Athivaram Village, Nellore district, has added an installed capacity of 25,000 MT per annum with an investment of Rs 32 crore. Strategically located near industrial corridors and ports, the unit will cater to sectors including renewable energy, EVs, semiconductors, e-commerce, warehousing, data centers, automotive, and infrastructure across South and West India.
At Kichha, the new Box Column Line, built with an investment of Rs 21 crore, enhances annual production capacity by 15,000 MT. The advanced line, equipped with automation and precision tooling, can manufacture large-format box sections up to 1500 x 1500 mm from 50 mm thick plates, designed for high-rise steel structures and data centers.
Interarch said the expansions reflect its commitment to innovation, sustainability, and the ‘Make in India’ vision, as it continues to strengthen its leadership in turnkey pre-engineered and multi-storey steel building solutions.
At the time of writing, shares were trading at Rs 2,132.90, up 2.90% on NSE.
Disclaimer
The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
